Expertise in
1
conditions

Michael S. Samuel

Frome Road, 
Adelaide, SA, AU 
Expertise in
1
conditions
Frome Road, 
Adelaide, SA, AU 

Overview

Michael Samuel practices practicing medicine in Adelaide, Australia.

Mr. Samuel is highly rated in 1 condition, according to our data. His clinical expertise encompasses Triple-Negative Breast Cancer, Myelodysplastic Syndrome (MDS), Glioblastoma, Astrocytoma, and Lithotripsy.

He is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Frome Road, Adelaide, SA 5000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Biological
Study Drugs: CPX-351, Fludarabine, Melphalan, Rabbit Anti-Human T-Lymphocyte Globulin, Haplo-Cord Stem Cell Transplantation
Study Phase: Phase 1
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

69 Total Publications

Overlapping MHC class I/II Epitopes Program cDC1-like Differentiation of Monocyte-Derived Dendritic Cells via mTORC1 Signaling Inhibition.
Overlapping MHC class I/II Epitopes Program cDC1-like Differentiation of Monocyte-Derived Dendritic Cells via mTORC1 Signaling Inhibition.
Journal: bioRxiv : the preprint server for biology
Published: April 17, 2026

Frequently Asked Questions about Michael S. Samuel

Is Michael S. Samuel a top-rated expert for Triple-Negative Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Michael S. Samuel is classified as an Advanced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael S. Samuel participate in research or clinical trials?

Yes. Michael S. Samuel has published 69 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Michael S. Samuel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Samuel's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile